Tech Center 1600 • Art Units: 1642 1671
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17627502 | ANTI-GRP78 ANTIBODIES AND METHOD OF USE THEREOF | Non-Final OA | Washington University |
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | Non-Final OA | ETH ZÜRICH |
| 17819182 | ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS | Non-Final OA | Denali Therapeutics Inc. |
| 16977547 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | Final Rejection | Poseida Therapeutics, Inc. |
| 18311155 | NEOANTIGENS AND METHODS OF THEIR USE | Non-Final OA | BioNTech US Inc. |
| 17788987 | ANTI-CDCP1 ANTIBODY | Non-Final OA | CHIOME BIOSCIENCE INC. |
| 17996837 | BISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES | Non-Final OA | Virtuoso BINco, Inc. |
| 17785011 | ANTI-SERUM ALBUMIN ANTIBODIES | Final Rejection | CULLINAN THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy